Regeneron Pharmaceuticals Revenue 2006-2021 | REGN

Regeneron Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Regeneron Pharmaceuticals revenue for the quarter ending June 30, 2021 was $5.139B, a 163.24% increase year-over-year.
  • Regeneron Pharmaceuticals revenue for the twelve months ending June 30, 2021 was $12.384B, a 67.64% increase year-over-year.
  • Regeneron Pharmaceuticals annual revenue for 2020 was $8.497B, a 29.58% increase from 2019.
  • Regeneron Pharmaceuticals annual revenue for 2019 was $6.558B, a 27.44% increase from 2018.
  • Regeneron Pharmaceuticals annual revenue for 2018 was $5.146B, a 12.37% decline from 2017.
Regeneron Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $8,497
2019 $6,558
2018 $5,146
2017 $5,872
2016 $4,860
2015 $4,104
2014 $2,820
2013 $2,105
2012 $1,378
2011 $446
2010 $459
2009 $379
2008 $238
2007 $125
2006 $63
2005 $66
Regeneron Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $5,139
2021-03-31 $2,529
2020-12-31 $2,423
2020-09-30 $2,294
2020-06-30 $1,952
2020-03-31 $1,828
2019-12-31 $1,864
2019-09-30 $1,744
2019-06-30 $1,578
2019-03-31 $1,373
2018-12-31 $363
2018-09-30 $1,664
2018-06-30 $1,608
2018-03-31 $1,512
2017-12-31 $1,582
2017-09-30 $1,501
2017-06-30 $1,470
2017-03-31 $1,319
2016-12-31 $1,227
2016-09-30 $1,220
2016-06-30 $1,213
2016-03-31 $1,201
2015-12-31 $1,098
2015-09-30 $1,137
2015-06-30 $999
2015-03-31 $870
2014-12-31 $802
2014-09-30 $726
2014-06-30 $666
2014-03-31 $626
2013-12-31 $610
2013-09-30 $597
2013-06-30 $458
2013-03-31 $440
2012-12-31 $415
2012-09-30 $428
2012-06-30 $304
2012-03-31 $232
2011-12-31 $123
2011-09-30 $103
2011-06-30 $108
2011-03-31 $112
2010-12-31 $134
2010-09-30 $106
2010-06-30 $116
2010-03-31 $104
2009-12-31 $97
2009-09-30 $117
2009-06-30 $90
2009-03-31 $75
2008-12-31 $56
2008-09-30 $66
2008-06-30 $61
2008-03-31 $56
2007-12-31 $65
2007-09-30 $22
2007-06-30 $22
2007-03-31 $16
2006-12-31 $10
2006-09-30 $16
2006-06-30 $19
2006-03-31 $18
2005-12-31 $17
2005-09-30 $16
2005-06-30 $16
2005-03-31 $16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $61.217B $8.497B
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76